



CLAIMS

1. A double stranded RNAi oligonucleotide (dsRNAi) capable of inhibiting the protein expression of MARC1, wherein said dsRNAi comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex region, and wherein the sense and antisense strands are selected from the group consisting of
 - (i) the sense and antisense strands comprise the nucleotide sequences set forth in SEQ ID NOs: 1543 and 1579, respectively;
 - (ii) the sense and antisense strands comprise the nucleotide sequences set forth in SEQ ID NOs: 1560 and 1596, respectively;
 - (iii) the sense and antisense strands comprise the nucleotide sequences set forth in SEQ ID NOs: 1568 and 1604, respectively; and
 - (iv) the sense and antisense strands comprise the nucleotide sequences set forth in SEQ ID NOs: 1553 and 1589, respectively.
2. A double stranded RNAi oligonucleotide (dsRNAi) for inhibiting the expression of MARC1, wherein said dsRNAi comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a MARC1 RNA transcript, wherein
 - (i) the sense strand comprises the sequence and all of the modifications of 5'-mGs-mG-mC-mU-mA-mG-mA-fG-fA-fA-fG-mA-mA-mA-mG-mU-mU-mA-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1615), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fUs-fA-fA-mC-fU-mU-mU-fC-mU-mU-mC-fU-mC-mU-mA-mG-mC-mCs-mGs-mG-3' (SEQ ID NO: 1651), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =




(ii) the sense strand comprises the sequence and all of the modifications of 5'-mAs-mG-mA-mA-mC-mG-mA-fA-fA-fG-fU-mU-mA-mU-mA-mU-mG-mG-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1632), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fCs-fC-fA-mU-fA-mU-mA-fA-mC-mU-mU-fU-mC-mG-mU-mU-mC-mUs-mGs-mG-3' (SEQ ID NO: 1668), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =




(iii) the sense strand comprises the sequence and all of the modifications of 5'-mAs-mA-mG-mU-mU-mG-mA-fC-fU-fA-fA-mA-mC-mU-mU-mG-mA-mA-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-

mU-mG-mC-3' (SEQ ID NO: 1640), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fUs-fU-fC-mA-fA-mG-mU-fU-mU-mA-mG-fU-mC-mA-mA-mC-mU-mUs-mGs-mG-3' (SEQ ID NO: 1676), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =




or

(iv) the sense strand comprises the sequence and all of the modifications of 5'-mUs-mG-mU-mG-mA-mA-mU-fA-fA-fA-fU-mG-mG-mA-mA-mG-mC-mU-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1625), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fAs-fG-fC-mU-fU-mC-mC-fA-mU-mU-mU-fA-mU-mU-mC-mA-mC-mAs-mGs-mG-3' (SEQ ID NO: 1661), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =




3. The double stranded RNAi oligonucleotide (dsRNAi) of claim 2, wherein the sense strand comprises the sequence and all of the modifications of 5'-mGs-mG-mC-mU-mA-mG-mA-fG-fA-fA-fG-mA-mA-mA-mG-mU-mU-mA-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1615), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fUs-fA-fA-mC-fU-mU-mU-fC-mU-mU-mC-fU-mC-mU-mA-mG-mC-mCs-mGs-mG-3' (SEQ ID NO: 1651), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc=




4. The double stranded RNAi oligonucleotide (dsRNAi) of claim 2, wherein the sense strand comprises the sequence and all of the modifications of 5'-mAs-mG-mA-mA-mC-mG-


mA-fA-fA-fG-fU-mU-mA-mU-mA-mU-mG-mG-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1632), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fCs-fC-fA-mU-fA-mU-mA-fA-mC-mU-mU-fU-mC-mG-mU-mU-mC-mUs-mGs-mG-3' (SEQ ID NO: 1668), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =



5. The double stranded RNAi oligonucleotide (dsRNAi) of claim 2, wherein the sense strand comprises the sequence and all of the modifications of 5'-mAs-mA-mG-mU-mU-mG-mA-fC-fU-fA-fA-mA-mC-mU-mU-mG-mA-mA-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1640), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fUs-fU-fC-mA-fA-mG-mU-fU-mU-mA-mG-fU-mC-mA-mA-mC-mU-mUs-mGs-mG-3' (SEQ ID NO: 1676), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =



6. The double stranded RNAi oligonucleotide (dsRNAi) of claim 2, wherein the sense strand comprises the sequence and all of the modifications of 5'-mUs-mG-mU-mG-mA-mA-mU-fA-fA-fA-fU-mG mG-mA-mA-mG-mC-mU-mA-mA-mG-mC-mA-mG-mC-mC-mG-[ademA-GalNAc]-[ademA-GalNAc]-[ademA-GalNAc]-mG-mG-mC-mU-mG-mC-3' (SEQ ID NO: 1625), and wherein the antisense strand comprises the sequence and all of the modifications of 5'-MePhosphonate-4O-mUs-fUs-fAs-fG-fC-mU-fU-mC-mC-fA-mU-mU-mU-fA-mU-mU-mC-mA-mC-mAs-mGs-mG-3' (SEQ ID NO: 1661), wherein mC, mA, mG, and mU = 2'-OMe ribonucleosides; fA, fC, fG, and fU = 2'F ribonucleosides; s = phosphorothioate, and wherein ademA-GalNAc =



7. A pharmaceutical composition comprising the double stranded RNAi oligonucleotide of any one of claims 2 to 6, and a pharmaceutically acceptable carrier, delivery agent or excipient.
8. Use of a therapeutically effective amount of the double stranded RNAi oligonucleotide of any one of claims 2 to 6 in the manufacture of a medicament for the treatment of a disease or condition associated with MARC1 expression in hepatocytes selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic steatohepatitis (ASH).
9. A kit comprising the double stranded RNAi oligonucleotide of any one of claims 2 to 6, a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration to a subject having a disease, disorder or condition associated with MARC1 expression selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcoholic steatohepatitis (ASH).